Explore federal awards
Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
Export these results to CSV · 12 matching records
TO PROVIDE MONITORING SERVICES FOR ONE (1) PHASE III CLINICAL TRIAL, A5300B/PHOENIXDepartment of Health and Human Services$5.7M obligationsEnds Dec 14, 2025
ADVANCED RESEARCH AND DEVELOPMENT ACTIVITIES FOR NOVEL IMMUNOGENICITY ASSAYS AND SAMPLE COLLECTION TECHNOLOGIES AS PART OF BARDA?S CONTINUING SUPPORT FOR COVID-19 VACCINE…Department of Health and Human Services$126.5M obligationsEnds Sep 28, 2029
TASK ORDER AWARD- PHASE I CLINICAL TRIALS FOR THE DEVELOPMENT OF NEUROTHERAPEUTICS- DTI-117 IN HEALTHY VOLUNTEERS/SAD AND MAD CTDepartment of Health and Human Services$2.0M obligationsEnds Apr 28, 2027
REGULATORY MANAGEMENT CENTER (RMC)Department of Health and Human Services$17.4M obligationsEnds Oct 31, 2026
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) CLINICAL SITE MONITORING CENTER (CSMC)Department of Health and Human Services$36.4M obligationsEnds Jun 29, 2027
NIAID CLINICAL SITE MONITORING (NCSM)Department of Health and Human Services$73.2M obligationsEnds Jan 31, 2027
TASK ORDER 75N93022F00001 BASE AWARDDepartment of Health and Human Services$905.5K obligationsEnds Jan 13, 2027
EPCTUDepartment of Health and Human Services$2.8M obligationsEnds Jan 31, 2026
BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC…Department of Health and Human Services$117.4M obligationsEnds Sep 30, 2030
BUCKPITT-PHASE I SINGLE ASCENDING DOSE STUDY-BPN-19186 (EC5026) PROTOCOL DEVELOPMENT AND FINALIZATION AND DATABASE BUILD AND BIOANALYTICAL METHODS DEVELOPMENT FOR CLINICAL TRIAL…Department of Health and Human Services$1.8M obligationsEnds Mar 10, 2025
FIRST IN HUMAN RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SINGLE ASCENDING DOSE (SAD) PHASE I STUDYDepartment of Health and Human Services$2.8M obligationsEnds Jun 30, 2026
PHASE I RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICSDepartment of Health and Human Services$305.8K obligationsEnds Jun 30, 2026